Clinical Trials Logo

Clinical Trial Summary

Membrane plasmapheresis is one of the methods for treating immune diseases. Plasmapheresis removes autoantibodies and immune complexes, paraproteins, lipoproteins and reduces the concentration of cytokines. In membrane plasmapheresis, plasma is separated from blood cells by a highly permeable membrane. The filtered plasma is then discarded and replaced with replacement fluid. During the procedure, there is an activation of the coagulation system, because of the extracorporeal blood circulation. The anticoagulation during the procedure is therefore necessary.


Clinical Trial Description

Standard heparin or citrate is routinely used as a method of anticoagulation in plasmapheresis. Citrate provides effective anticoagulation that is completely limited to extracorporeal circulation. Patients who are at increased risk for bleeding, anticoagulation with citrate is a more appropriate method than standard heparin, while in other patients both methods are equivalent. Citrate anticoagulation is performed by infusing citrate into the arterial line of the extracorporeal system. Citrate binds to plasma calcium and thus inhibits coagulation in the system. Calcium is added to the venous line of the system (when blood returns to the patient) to maintain a normal plasma ionized calcium concentration. Lowering the ionized calcium in the blood in the extracorporeal circulation inhibits the coagulation and activation of other systems (platelets, leukocytes, complement), which affects the biocompatibility of the artificial material and the whole procedure. Biocompatibility is extremely important, since the contact of blood with artificial material activates both the humoral and cellular systems. As part of the humoral immune system, complement is activated by the production of C3, C4 and C5, factor XIIa, there is also an increase in the production of bradykinin, kallikrein, quinine and plasmin, and some proteins are denatured (gamma globulins, fibrinogen, albumins). When the cellular immune system is activated, lymphocytosis can occur and the is also change in function of phagocytes. All previous studies show that regional anticoagulation with citrate improves biocompatibility in hemodialysis procedures (compared to heparin anticoagulation), but no direct comparison in plasmapheresis has been observed in the literature so far. Therefore, the investigators want to conduct a prospective randomized study comparing several parameters of heparin and citrate anticoagulation biocompatibility during plasmapheresis. The aim of the study is to demonstrate better biocompatibility in citrate anticoagulation compared to heparin. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05191290
Study type Interventional
Source University Medical Centre Ljubljana
Contact Jakob Gubensek, MD, PhD
Email [email protected]
Status Recruiting
Phase Phase 4
Start date December 28, 2021
Completion date December 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT02705976 - Prospective Trial of a Validated Algorithm for Warfarin Dosing N/A
Recruiting NCT04139525 - Comparison of Citrate and Heparin Anticoagulation During Hemodialysis With MCO PES-PVP (Theranova) Membrane N/A
Completed NCT01907048 - Patient and Physician Knowledge of Key Safety Messages
Recruiting NCT03419923 - Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage N/A
Completed NCT03575936 - Enhanced Pharmacist-Managed Anticoagulation Service in a University-based Family Medicine Clinic N/A
Completed NCT02714855 - Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France N/A
Recruiting NCT01314235 - Influence of Clonidine on Thrombozytes of Blood of Patients Under Anticoagulation Therapy With ASS and Clopidogrel N/A
Not yet recruiting NCT04059965 - AntiCoagulation Tracking InterVention and Evaluation N/A
Recruiting NCT02987192 - Minimally Invasive Lumbar Aneasthesia Used for Cesarean Section N/A
Completed NCT01477528 - Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)
Recruiting NCT04405232 - Coagulopathy in COVID19 - A Multi-Centre Observational Study in UK
Recruiting NCT02761941 - Excessive Warfarin Anticoagulation - Causes and Consequences N/A
Completed NCT02392104 - Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service N/A
Completed NCT01884337 - Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery Phase 4
Recruiting NCT03473132 - Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC) Phase 4
Completed NCT03662594 - Growth of High-Quality Oxides on The Inner Surface of ECMO Circuit by ALD to Reduce Thrombus Formation N/A
Recruiting NCT03910933 - Electronic KIDCLOT Interactive Thrombosis/Thrombophilia Education; A Quality Assurance Initiative
Active, not recruiting NCT02640222 - APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
Completed NCT02492828 - Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden N/A
Completed NCT03684395 - Accessibility to New Drugs Versus SOC in Sweden